Glenmede Trust Co. NA Has $916,000 Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Glenmede Trust Co. NA grew its stake in shares of Repligen Co. (NASDAQ:RGEN) by 13.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,158 shares of the biotechnology company’s stock after purchasing an additional 728 shares during the quarter. Glenmede Trust Co. NA’s holdings in Repligen were worth $916,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in RGEN. Andra AP fonden acquired a new position in Repligen during the second quarter worth $25,000. Lazard Asset Management LLC increased its stake in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. lifted its stake in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new position in Repligen during the second quarter worth about $33,000. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 0.1 %

Shares of NASDAQ:RGEN opened at $150.46 on Tuesday. The business’s 50 day simple moving average is $141.18 and its 200 day simple moving average is $142.27. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a market capitalization of $8.43 billion, a P/E ratio of -406.64, a P/E/G ratio of 4.53 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period in the prior year, the firm posted $0.23 EPS. Repligen’s quarterly revenue was up 9.7% on a year-over-year basis. On average, research analysts anticipate that Repligen Co. will post 1.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, November 22nd. Finally, Wells Fargo & Company assumed coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average target price of $190.25.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is currently owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.